Natco Pharma Clarifies Novo Nordisk Patent Dispute Status to BSE

Natco Pharma has provided an official clarification to BSE regarding the ongoing patent litigation with Novo Nordisk over semaglutide, following a stock exchange query about recent news coverage of the legal proceedings.

BSE Query and Company Response

The company responded to BSE's inquiry dated January 7, 2026, addressing questions about the patent dispute proceedings and their potential impact. The pharmaceutical company clarified that the litigation has been continuing for several months with the outcome still awaiting judicial determination.

Query Parameter:	Company Response
Litigation Status:	Continuing for several months, outcome awaiting
Material Financial Impact:	No material financial impact as of now
Disclosure Compliance:	Consistent adherence to SEBI LODR Regulations

Patent Dispute Background

The legal proceedings center around Natco Pharma's petition to revoke Novo Nordisk's semaglutide patent. The High Court had previously issued a notice to the Danish pharmaceutical giant, marking a significant development in the patent challenge. Semaglutide is a medication primarily used for treating diabetes and weight management.

Regulatory Compliance Statement

Natco Pharma emphasized its commitment to regulatory compliance, stating that the company has been consistently making disclosures to stock exchanges as required under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company assured continued adherence to these regulations.

Current Status and Future Disclosures

The company indicated that upon the outcome of the litigation, it will inform the stock exchanges in due course based on the material impact of the litigation on the financial performance of the company. As of the current date, the company reports no material financial impact from the ongoing legal proceedings.

The clarification was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, reinforcing the company's transparent approach to stakeholder communication regarding significant legal developments.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.85%	+0.74%	-2.56%	-6.56%	-31.41%	-2.66%

Natco Pharma , a prominent player in the pharmaceutical industry, has announced a significant addition to its leadership team. The company's Board has approved the appointment of Amit Parekh as Executive Vice President-Finance and Accounts, effective from December 2, 2025.

Key Appointment Details

Position	Appointee	Effective Date
Executive Vice President-Finance and Accounts	Amit Parekh	December 2, 2025

Succession Planning

As part of Natco Pharma's structured succession planning, Amit Parekh is slated to succeed S.V.V.N. Appa Rao as Chief Financial Officer. This transition is expected to take place at the Board meeting scheduled for February 2026, subject to necessary approvals.

Implications for Natco Pharma

The appointment of Amit Parekh signifies Natco Pharma's commitment to strengthening its financial leadership and ensuring a smooth transition in key executive roles. This strategic move may contribute to:

Continuity in financial management
Enhanced strategic financial planning
Smooth transition of CFO responsibilities

This appointment demonstrates Natco Pharma's focus on maintaining strong financial leadership and planning for the future in an increasingly competitive pharmaceutical landscape.